Suppr超能文献

密集型新辅助蒽环类序贯每周紫杉醇治疗三阴性乳腺癌患者的疗效观察。

Observation Effectiveness of Dose-Dense Neoadjuvant Anthracycline Sequential Weekly Paclitaxel for Triple-Negative Breast Cancer Patients.

机构信息

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China.

出版信息

Clin Breast Cancer. 2023 Jun;23(4):423-430. doi: 10.1016/j.clbc.2023.02.009. Epub 2023 Feb 21.

Abstract

INTRODUCTION/BACKGROUND: To investigate the differences in pathological response and survival outcomes between dose-dense and conventional-interval neoadjuvant chemotherapy (NAC) in patients with triple-negative breast cancer (TNBC).

PATIENTS AND METHODS

Patients with TNBC who received NAC including epirubicin plus cyclophosphamide followed by weekly paclitaxel were included. A total of 494 patients were divided into either the dose-dense anthracycline (ddEC-wP) group or conventional interval anthracycline (EC-wP) group.

RESULTS

The breast pathological complete response (bpCR, ypT0/is) rate was 45.3% (n = 101) in the dose-dense group and 34.3% (n = 93) in the conventionally scheduled group, which was a significant difference (P = .013), and in the 251 pN+ cases, the lymph node pathological complete response (LNpCR, ypN0) rate was 57.9% (n = 62) in the dose-dense group and 43.7% (n = 63) in the conventionally scheduled group, which was a significant difference (P = .026) in the univariate analysis. In the multivariate logistic regression analysis, 3 variables were predictive of bpCR: pathological type, surgical methods and type of chemotherapy, with P values of .012, .001 and .021, respectively. Two variables were predictive of LNpCR: type of chemotherapy and Her-2 expression, with P values of .039 and .020, respectively. After a median follow-up of 54 months, there was no significant difference in survival for disease-free survival (DFS) (hazard ratio [HR], 0.788; 95% confidence interval [CI], 0.508 to 1.223; P = .288), distant disease-free survival (DDFS) (HR, 0. 709; 95% CI, 0.440 to 1.144; P = .159) or overall survival (OS) (HR, 0. 750; 95% CI, 0.420 to 1.338; P = .330) between the 2 groups.

CONCLUSION

Our study demonstrated that TNBC achieved a higher bpCR rate and LNpCR rate after dose-dense neoadjuvant chemotherapy than the conventional scheme. The survival benefit of the 2 groups did not reach statistical difference.

摘要

介绍/背景:为了研究三阴性乳腺癌(TNBC)患者密集剂量和常规间隔新辅助化疗(NAC)之间的病理反应和生存结果的差异。

患者和方法

接受包括表柔比星加环磷酰胺随后每周紫杉醇的 NAC 的 TNBC 患者被纳入研究。共有 494 名患者被分为密集型蒽环类药物(ddEC-wP)组或常规间隔蒽环类药物(EC-wP)组。

结果

密集组的乳房病理完全缓解(bpCR,ypT0/is)率为 45.3%(n=101),常规组为 34.3%(n=93),差异有统计学意义(P=0.013),在 251 例 pN+病例中,淋巴结病理完全缓解(LNpCR,ypN0)率在密集组为 57.9%(n=62),在常规组为 43.7%(n=63),差异有统计学意义(P=0.026)。在单变量逻辑回归分析中,有 3 个变量与 bpCR 相关:病理类型、手术方法和化疗类型,P 值分别为 0.012、0.001 和 0.021。有 2 个变量与 LNpCR 相关:化疗类型和 Her-2 表达,P 值分别为 0.039 和 0.020。中位随访 54 个月后,两组间无病生存(DFS)(风险比[HR],0.788;95%置信区间[CI],0.508 至 1.223;P=0.288)、远处无病生存(DDFS)(HR,0.709;95%CI,0.440 至 1.144;P=0.159)或总生存(OS)(HR,0.750;95%CI,0.420 至 1.338;P=0.330)无显著差异。

结论

本研究表明,与常规方案相比,密集型新辅助化疗后 TNBC 达到更高的 bpCR 率和 LNpCR 率。两组的生存获益未达到统计学差异。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验